Page 23 - Pharma Companies

Gilead Sciences developing easy-to-administer version of remdesivir

Remdesivir is the only drug so far that has been shown to help patients with Covid-19, but Gilead and other companies are looking for ways to make it work better.

Covid-19 crisis: Indian drug companies yet to get nod to market remdesivir

The USFDA granted remdesivir an emergency use authorization for the treatment of hospitalized patients with severe Covid-19

Pharma companies refine SOPs after Covid-19 cases, deaths in Gujarat

Apart from the general sanitization of buses and plants, Lupin and many other pharma companies have now started sanitising raw material entering the plant

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Covid-19 crisis prompts India to look for global partners in health care

Medical devices industry has potential to attract Rs 70,000 crore in 5 years

First copies of Gilead coronavirus drug to start selling in Bangladesh

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

AstraZeneca says data from Covid-19 vaccine's phase-1 trials to be out soon

Once the late stage trials begin, the company simultaneously will start working on the global manufacturing capabilities.

GlaxoSmithKline Q4 consolidated net profit declines 6% to Rs 138 cr

The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries

PM Modi announces Rs 20 trillion stimulus package to jump-start economy

'Self-reliant India' package is around 10% of GDP; lockdown 4.0 is on with new guidelines

Price drives growth of Rs 1.4 trillion pharma market, hits a five-year high

The rapid growth of the trade generics market which accounts for a third of pharma volumes is another trend which is impacting volume as well as overall growth of the branded segment

Day 1 of lockdown 3.0: India limps back, but industry still in limbo

With public transport still not allowed in 130 red-zone districts, which comprise some of the economically important urban centres, people took out their private vehicles.

Covid-19 lockdown: Domestic pharma growth takes hit as stock piles up

Inventory days have gone up from 31 days as on March 22 to 41 days as on April 22

Coronavirus impact: Top pharma companies fare better during lockdown

New launches stagnate as fresh prescriptions dry up

Gilead's antiviral drug remedesivir being made in India on trial basis

Local drug makers start developing patented drug as govt too wishes to try it on Indians

Order inflow to improve for manufacturers of specialty chemicals

Galaxy Surfactants, SRF, Aarti Industries among companies to benefit given supply of essential ingredients, alternative supply chain to China and weak crude oil prices

Indian pharma majors step in to develop, import coronavirus test kits

The rapid test uses a blood sample and gives results based on detecting the presence of certain antibodies that react to the coronavirus protein

Private labs wait for govt go-ahead to launch coronavirus test kits

ICMR on Saturday said all hospitalised patients who have pneumonia or severe acute respiratory illness will be tested for Covid-19.

The post-COVID-19 world

Policymakers and pharma companies will have to work together to speed up trials of new vaccines and legislate to ensure essential drugs and tests are affordable and available

Covid-19 won't impact credit rating of pharma firms for now: Ind-Ra

If the disruption spills beyond the next 9 to 12 months, some of the higher rated corporates could face downward pressure